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ABSTRACT: Inﬂuenza is an infectious disease that represents
an important public health burden, with high impact on the
global morbidity, mortality, and economy. The poor protection
and the need of annual updating of the anti-inﬂuenza vaccine,
added to the rapid emergence of viral strains resistant to current
therapy make the need for antiviral drugs with novel
mechanisms of action compelling. In this regard, the viral
RNA polymerase is an attractive target that allows the design of
selective compounds with reduced risk of resistance. In previous
studies we showed that the inhibition of the polymerase acidic
protein-basic protein 1 (PA−PB1) interaction is a promising
strategy for the development of anti-inﬂuenza agents. Starting
from the previously identiﬁed 3-cyano-4,6-diphenyl-pyridines,
we chemically modiﬁed this scaﬀold and explored its structure−activity relationships. Noncytotoxic compounds with both the
ability of disrupting the PA−PB1 interaction and antiviral activity were identiﬁed, and their mechanism of target binding was
clariﬁed with molecular modeling simulations.
■ INTRODUCTION
Despite the eﬀorts in antiviral research, inﬂuenza (Flu) is an
infectious disease that still represents an important public
health burden aﬀecting 5−10% of the World’s population,
resulting in 3−5 million severe cases and in 250−500
thousands deaths each year.1 It is caused by the ribonucleic
acid (RNA) viruses of the Orthomyxoviridae family, and they
are classiﬁed in A, B, and C according to their antigenic
diﬀerences.2−4 Among these, inﬂuenza A virus (FluA) infects a
variety of animals as well as humans. Hemagglutinin (HA) and
neuraminidase (NA) are the two major viral antigenic
glycoproteins, and the 18 HA (H1−H18) and 11 NA (N1−
N11) identiﬁed in FluA virus result in the generation of distinct
viral subtypes.5 Some of them are responsible for severe upper
respiratory diseases in humans that occur in both seasonal
epidemics and sporadic pandemics associated with high
morbidity and mortality. Millions of deaths were recorded in
the most important pandemics of the last century.6,7 In
chronological order, these were the Spanish Flu (H1N1 strain,
in 1918),8,9 the Asian Flu (H2N2 strain, in 1957),9 the Hong
Kong Flu (H3N2 strain, in 1968),9 and the “swine” Flu (H1N1
strain, in 2009).10 Recently, the zoonotic infection caused by
the “avian” FluA subtype H7N9 registered a fatality rate of 25%
of the conﬁrmed cases. In this outbreak, it was proven that
most of the patients were directly infected from poultry,
although the existence of limited human-to-human spread
could not be excluded. However, the possibility of sustained
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acquisition of human-to-human transmission capabilities by this
pathogen could result in a devastating worldwide health
problem, raising much concern for its pandemic potential.11
Reassortments of the genetic material between diﬀerent
strains allow the virus to avoid host detection systems and the
emergence of the extremely aggressive viruses responsible for
the pandemics. These, antigenic drift in particular, are
complicating factors hampering the development of an eﬀective
and universal anti-Flu vaccine, and thus, the development of
anti-inﬂuenza drugs is essential for the ﬁght of future Flu
outbreaks.12,13 Clinical therapy relies only on two classes of
drugs that inhibit either the M2 ion channel (amantadine and
rimantadine) or NA (e.g., oseltamivir and zanamivir).14,15 M2
ion channel inhibitors were the ﬁrst anti-inﬂuenza drugs
approved. However, they are no longer recommended due to
their serious side eﬀects on the central nervous system (CNS)
and the very rapid emergence of drug-resistant inﬂuenza
strains.14−16 Furthermore, drug-resistant FluA viruses are also
emerging for the current ﬁrst line therapy (NA inhibitors),
making the discovery of novel antiviral strategies essen-
tial.14,15,17,18
A new molecular target that was identiﬁed in the past few
years is FluA RNA-dependent RNA polymerase (RdRp), a
protein complex essential for the viral replication and
pathogenesis. Indeed, it is responsible for viral RNA replication
and an endonuclease activity for the “cap-snatching”, which is
necessary for both transcription initiation and translation.19
Importantly, FluA RdRp is signiﬁcantly diﬀerent from human
polymerases and it is highly conserved among the diﬀerent Flu
subtypes, facilitating the design of selective compounds with
reduced probability of virus resistance development. RdRp is a
complex of three virus-encoded subunits: the polymerase acidic
protein (PA), the polymerase basic protein 1 (PB1), and the
polymerase basic protein (PB2). Only the correct assembly of
the three subunits allows the correct functioning of the
enzyme.19−23 Thus, an attractive mechanism of FluA RdRp
inhibition is the disruption of the PA−PB1 protein−protein
interaction. This is a very promising strategy for anti-inﬂuenza
drug discovery, as demonstrated by the emergence of protein−
protein interaction (PPI) small-molecule inhibitors in recent
years.14,15,24−36 Among these, a hit compound disrupting the
PA−PB1 interaction was identiﬁed through a high-throughput
docking as a potential FluA polymerase inhibitor and from this
encouraging result a small library of purchased analogues was
evaluated. With IC50 values in the micromolar range, the
activity related to the 3-cyano-4,6-diphenyl-pyridine scaﬀold
was conﬁrmed as being responsible for the disruption of the
PA−PB1 complex through the interaction of these molecules
with the C-terminal domain of PA, mimicking the hydrophilic
N-terminal portion of PB1 (residues 1−4).35 In order to obtain
a better understanding of the structure−activity relationship
(SAR) of this promising class of compounds and aiming the
improvement of their activity, a hit optimization process was
performed in the study presented here.
■ RESULTS AND DISCUSSION
Hit Exploration. Starting from a simpliﬁed structure
(compound 1) of the novel class of inhibitors identiﬁed in
the previous virtual screening campaign,35 a series of analogues
was designed for a better understanding of the underlying
structure−activity relationships. The 3-cyano-4,6-diphenyl-
pyridine scaﬀold was systematically modiﬁed by either
removing or replacing molecule portions. Furthermore,
attempts to increase compound solubility (e.g., 2), to address
the possibility of a covalent interaction between the protein and
the thioether (e.g., 5 and 6), and to increase the synthetic
feasibility (e.g., 14 and 15) were considered. All the synthesized
compounds can be found in Table 1.
Chemistry. Due to the removing and replacing strategy
adopted in the design of the molecules, several synthetic routes
were applied. However, 2-chloro-4,6-diphenylnicotinonitrile
(16) was used as a common precursor for the synthesis of
several compounds (1, 3−8, and 10), as shown in Scheme 1. Of
these, 1, 3, 4, 7, and 8 were obtained by nucleophilic aromatic
substitution using the appropriate nucleophile (compounds
17a−e). Reaction conditions diﬀered according to the reactant
properties, and in several cases, temperature control was
important in order to avoid the formation of a highly
ﬂuorescent ring-closed side product. Extensive analysis was
performed to conﬁrm the regiochemistry of these reactions. An
eﬃcient Heck coupling reaction between N-(m-tolyl)-
acrylamide (18) and precursor 16 was performed for the
synthesis of compound 6, which has a trans stereochemistry as
indicated by the large J constant between the two vinylic
protons (14.8 Hz). This alkene was then reduced to the
saturated analogue 5. Compound 10 was synthesized by
hydrogenolysis of the C−Cl bond of compound 16.
Precursors 17d and 17e were prepared through the neat
acylation of 3-methyl-aniline (19) with either mercapto-
propionic acid (20) or dihydrothiophen-2(3H)-one (21),
respectively (Scheme 2). Intermediate 18 was obtained through
the acylation of 3-methyl-aniline (19) with acryloyl chloride
(22, Scheme 2).
Final products 12, 13, 14, and 15 were synthesized by
aromatic nucleophilic substitution on the appropriate aromatic
electrophile 23a−d with the nucleophile 2-mercapto-N-(m-
tolyl)acetamide (17a) in acetonitrile, as shown in Scheme 3.
A diﬀerent synthesis approach was required for compound
11. As shown in Scheme 4, the pyridone 24 was chlorinated
with POCl3 to yield 2-chloro-4,6-diphenylpyridine (25), which
then reacted with thiol (17a) through a Cu-catalyzed aromatic
nucleophilic substitution, giving the ﬁnal product (11).
Scheme 5 reports the synthetic strategy used for compounds
2 and 9. The precursor 2-chloro-1-morpholinoethanone (28)
was synthesized through the reaction of morpholine (26) with
chloroacetyl chloride (27). Then, 4,6-diphenylpyridine-2-thiol
(29) was used as a nucleophile in the nucleophilic substitution
on 28 or iodomethane for the synthesis of the ﬁnal products 2
and 9, respectively.
Biological Evaluation of the Compounds. All the
synthesized molecules were evaluated for their inhibitory
activity against the PA−PB1 interaction. The abilities of the
test compounds to inhibit the physical interaction between PA
and PB1 and to block Flu virus replication were tested in
enzyme-linked immunosorbent assays (ELISA) and in plaque
reduction assays (PRA) in Mardin−Darby canine kidney
(MDCK) cells infected with FluA virus (A/PR/8/34 strain),
respectively. In order to exclude the possibility that the
observed antiviral activity might be due to toxic eﬀects on the
infected cells, compound cytotoxicity was also assessed in two
cell lines (MDCK and human embryonic kidney, HEK 293T)
by the MTT assay. In these studies, the PB1(1−15)-Tat peptide
37
was used as a positive control for inhibition in the ELISA, while
the broad-spectrum inhibitor of RNA viruses polymerases
Ribavirin (RBV)38 was used as a positive control in the PRA as
it inhibits viral polymerases, even though its mechanism of
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action does not involve the inhibition of PA−PB1 formation.
Moreover, the ﬁrst line therapeutic NA inhibitor Oseltamivir
(OSV)39 was included as a positive control in the PRA. The
results of the experiments are shown in Table 1. Most
importantly, data revealed for the ﬁrst time not only that the
chemical scaﬀold studied in this hit optimization process is able
to inhibit the formation of the FluA PA−PB1 complex with
comparable IC50 with respect to the control (PB1(1−15)-Tat
peptide), but also that it exhibits a good cytotoxicity proﬁle and
a low micromolar antiviral activity, comparable to RBV. Despite
less eﬃcient antiviral activity was recorded for our compound
family with respect to OSV, the family of compounds presented
here inhibits a target that is less-prone to mutations than NA,
for which resistance has frequently already emerged.
Lower activity in the ELISA experiments compared to the
PRA could be observed, in particular for compounds 1, 4, 14,
and 15. Compounds 1 and 14 exhibited a low-micromolar EC50
value in PRA (9.2 and 3.5 μM, respectively) and a 19−47-fold
higher IC50 value in ELISA (175 and 165 μM, respectively),
while 4 and 15 presented an EC50 around 30 μM in PRA (28.6
and 26.5 μM, respectively) and complete loss of the ability to
disrupt the PA−PB1 interaction in ELISA. In order to
investigate whether this could be due to the assay conditions,
the ELISA was repeated for all molecules with EC50 values
below 30 μM (1, 4, 8, 11, 14, and 15). In this assay (henceforth
mentioned as “Modiﬁed ELISA PA−PB1 Interaction Assay”),
compounds were dissolved in a similar medium to the one used
in the cell-based assays instead of the PBS buﬀer (see
Experimental Section). Similarly to the previous ELISA PA−
PB1 Interaction Assay, the PB1(1−15)-Tat peptide
37 was used as
a positive control for inhibition. As reported in Table 2, a
signiﬁcant improvement in the inhibitory activity was obtained
mainly for 1 and 15, which were more soluble in the DMEM
serum-free buﬀer with respect to the PBS one, while more
modest improvements were obtained for 11 and 14. The same
IC50 values were registered for compounds 4 and 8. As
expected, comparable IC50 values were also obtained for the
PB1(1−15)-Tat peptide in the two assay conditions, suggesting
that the medium was aﬀecting the behavior of some of our
compounds rather than the accessibility of the target site.
Data presented in both Table 1 and Table 2 are of great value
for the understanding of the general mechanism of action of the
3-cyano-4,6-diphenyl-pyridine scaﬀold. A signiﬁcant decrease in
Scheme 1. Synthesis of Compounds 1, 3−8, and 10a
aReagents and conditions: (i) DMF, K2CO3, rt, 1 h (for 1); MeCN, CuI, Cs2CO3, MWO 120 °C, 1.5 h (for 3); DMF, K2CO3, 45 °C, 18 h (for 4);
MeCN, K2CO3, 0 °C, 0.5 h then: rt, 3 h (for 7 and 8); (ii) DMF, Pd(OAc)2, TBAB, (o-tol)3P, NaOAc, 145 °C, 18 h; (iii) EtOAc, H2, Pd/C, rt, 11 h;
(iv) NaOAc, MeOH, H2, PdCl2, rt, 36 h.
Scheme 2. Synthesis of Precursors 17d, 17e, and 18a
aReagents and conditions: (i) rt, 1 h, then MWO, 180 °C, 1 h; (ii)
MWO 120 °C → 240 °C, 28 h; (iii) TEA, THF, 0 °C, 2.5 h.
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activity was observed in the attempts of substituting the sulfur
atom (3, 4, 5, and 6), indicating the importance of this
heteroatom. Only for compound 4 the antiviral activity was
partially retained. The whole sulfur-containing side chain
appears to be also essential as its complete (10) or its partial
(9) removal resulted in a reduction or a complete loss of
activity. Nevertheless, a mild antiviral activity was observed for
compound 10. However, considering its signiﬁcant cytotoxicity
in MDCK cells and the high IC50 value in ELISA, its antiviral
activity in PRA might be related to cell toxicity rather than to
the inhibition of PA−PB1 interaction. This hypothesis is in
keeping with the observation that the compound 10 lacks of
one of the interaction with a relevant hydrophobic area within
the PA binding region. Only one methylene group should be
placed between the sulfur atom and the carbonyl moiety, as the
extension of the chain (7 and 8) increased cytotoxicity.
Furthermore, the 3-methyl substituted phenyl ring cannot be
replaced by a more hydrophilic group, as indicated by the
increased EC50 value of compound 2. Given the inactivity and
the higher cytotoxicity of 12 and 13, the two phenyl rings
directly attached to the pyridine ring (in positions 4 and 6)
appear to be essential in the molecular scaﬀold. Interestingly,
the removal of the cyano moiety linked to the same central core
(11) did not aﬀect activity. Good antiviral activity was observed
also with the substitution of the pyridine ring with a pyrimidine
one (14), but a lower ability to dissociate the PA−PB1 complex
and a higher cytotoxicity were detected as well. However, this
toxicity decreased with the introduction of two electron
withdrawing CF3 groups in the structure (15). For this
compound, a better IC50 value was obtained in the modiﬁed
ELISA, but a worse antiviral activity proﬁle in respect to
compounds 1, 8, 11, and 14 was also detected.
From these results, compounds 1, 11, and 15 emerged as the
most promising molecules since they display micromolar
inhibition of the PA−PB1 interaction (with IC50 values ranging
from 35.2 to 64.5 μM), interesting antiviral activity, and a good
cytotoxicity proﬁle with a selectivity index (SI) higher than 9.4.
Among the other compounds, 4 showed an antiviral activity
comparable to 15 and a good cytotoxicity proﬁle (SI > 8.7), but
no inhibition of the PA−PB1 interaction. Thus, aiming to
better understand the mechanism of action of these
compounds, the ability of 1, 4, 11, and 15 to inhibit FluA
RNA-dependent RNA polymerase (RdRp) enzymatic activity
in a cellular context was assessed by minireplicon assays in
transfected HEK 293T cells, using RBV38 as a reference
inhibitor. The results are presented in Table 3. All of the tested
compounds were found to inhibit the viral polymerase activity,
with encouraging EC50 values for compounds 11 and 15 (22.0
to 30.8 μM) in particular. Furthermore, from the results it
emerges that probably compound 1, in addition to the
inhibition of the PA−PB1 interaction, might be involved in
other mechanisms of action not related to the viral polymerase
activity because its low EC50 value in the PRA assay (9.2 μM)
does not reﬂect completely the activity in the minireplicon
assay (EC50 86.6 μM). Compound 4 inhibited the catalytic
activity of the viral RdRp in the 293T cells (EC50 46.3 μM),
indicating that this molecule might exert its antiviral eﬀects by
inhibiting the viral RdRp activity, but through a mechanism of
action that likely does not involve the PA−PB1 complex
disruption.
The ability of these compounds to inhibit the polymerase
activity in cells as well as the PA−PB1 interaction and the
formation of viral plaques is a substantial indication that the
most promising 4,6-diphenylpyridine (or pyrimidine) mole-
cules exert their anti-inﬂuenza activity through the disruption of
the PA−PB1 complex.
Molecular Modeling. In order to rationalize the SARs, all
the synthesized compounds were examined by means of
docking simulations within the PB1-binding site of PA in order
to produce their putative binding poses.
The 3-cyano-4,6-diphenylpyridine series was discovered with
a previous high-throughput docking study performed on a
homology model built using the FluA H1N1 sequence and two
PA−PB1 complexes templates (PDB IDs: 2ZNL20 and
3CM821).35 Subsequent to the publication of the manuscript
by Tintori et al.,35 a novel X-ray structure of FluA H17N10
RdRp was published (PDB ID: 4WSB)23 and comprised the
whole PA in complex with PB1, PB2, and a viral RNA
promoter. Since the C-terminal portion of PA (PAC) in 4WSB
is more complete than the structures used to build the PA−PB1
complex in silico (2ZNL and 3CM8), the two PAC were
compared in order to assess the quality of the homology model.
The two structures have 71.21% identity in sequence
alignment, and they superpose very well (RMSD 1.09 Å).
Remarkably, the superposition is even better in the PB1-
binding site region (RMSD of 0.537 Å), validating the reliability
of the homology model. The backbone superposition of the
homology model and PDB ID 4WSB is shown in Figure S1 of
the Supporting Information. Since biological evaluations were
performed on the FluA H1N1 strain and since the homology
model was assessed of good quality, for consistency purposes,
the homology model was used for the docking simulations.
Similarly to the procedure applied in the previous study,35
docking simulations were carried out with two widely used
programs (Glide40 and GOLD41) and the binding poses were
then compared. Most importantly, only the active compounds
reproduced the already reported binding model35 of the 3-
cyano-4,6-diphenyl-pyridine derivatives, conﬁrming the pro-
posed mode of binding of this class of inhibitors. The pose
obtained for compound 1 is shown in Figure 1 as an example.
Scheme 3. Synthesis of Compounds 12, 13, 14, and 15a
aReagents and conditions: (i) MeCN, K2CO3, rt, 30 min (for 12); MeCN, NaOAc, rt, 18 h then 40 °C, 5 d (for 13); MeCN, K2CO3, rt, 5 h (for
14); MeCN, K2CO3, 0 °C to rt, 2.5 h (for 15).
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In this model, two hydrogen bonds between the amide portion
of the ligands and residues Gln408 and Val621 resemble PB1−
PA interactions. When present in the ligand, a third hydrogen
bond occurs between the CN nitrogen of the compound and
Lys643 side chain amine. The three phenyl rings are
accommodated in three hydrophobic areas indicated as I
(Val621, Phe411, and Cys415), II (Pro620, Val628, and
His713), and III (Phe658, Leu666, Phe707, and Phe710) in
Table 1. Structure and Biological Activity of the Synthesized Compounds
aActivity of the compounds in the ELISA PA−PB1 interaction assays. Values represent the compound concentration (in μM) that reduces the
interaction between PA and PB1 by 50% (IC50).
bAntiviral activity of the compounds in plaque reduction assays against the Flu A/PR/8/34 strain.
Values represent the compound concentration (in μM) that inhibits 50% of plaque formation (EC50).
cCytotoxicity of the compounds exhibited in
the MTT assays. Values represent the compound concentration (in μM) that causes a 50% decrease in cell viability (CC50).
dCC50 assessed in HEK
293T cells. eCC50 assessed in MDCK cells.
fSelectivity index, deﬁned as the ratio between the CC50 value assessed in MDCK cells and the EC50
value. gCompound concentrations higher than those reported could not be tested in PRA due to cytotoxicity. All values represent the averages ± SD
of data derived from at least three independent experiments in duplicate. ND: not determined. NC: not calculated because of cytotoxicity or absence
of antiviral activity at tested concentrations.
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the ﬁgure. A further hydrophobic interaction involves Trp706
and the pyridine (or pyrimidine) ring of the small molecule.
Two examples of bad ligand placements within the binding
site are shown in Figure 2, where the conformations of 12 and
3 (cyan sticks) are compared with that of compound 1 (orange
sticks). As previously discussed, compounds lacking of
important portions of compound 1 were not able to reproduce
fundamental protein−ligand interactions in the docking
simulations. In particular, the increase of IC50 values of
molecules lacking of either one of the phenyl groups that
interact with the protein regions II and III could be explained
by the impossibility to form any of the important interactions,
most of the time presenting a completely diﬀerent binding
mode, as exempliﬁed in panel A in Figure 2. With the
substitution of the sulfur atom (compounds 3−5) and with the
introduction of a double bond (6) the eﬀective interactions
were sometimes partially reproduced (exempliﬁed in panel B in
Figure 2) or completely lost. The diﬀerent geometry properties
of the atoms substituting the sulfur atom and of the C−C
double bond do not allow the small molecule to assume a
suitable conformation for correct binding, resulting in a bad
docking pose and explaining the inactivity of these molecules.
Compounds 11, 14, and 15, all lacking the nitrile group, were
able to reproduce all the important interactions, except the
hydrogen bond with Lys643, thus overlapping very well with
the binding pose of 1 (Figure 3). The overlapping binding
Scheme 4. Synthesis of Compound 11a
aReagents and conditions: (i) POCl3, reﬂux, 4 d; (ii) DME, CuI, L-proline, K2CO3, reﬂux in sealed ampule, 30 h.
Scheme 5. Synthesis of Compounds 2 and 9a
aReagents and conditions: (i) K2CO3, THF, 0 °C to rt, 1 h; (ii-a) DMF, Cs2CO3, TBAI, rt, 1 h; (ii-b) 0 °C to rt, 2 h.
Table 2. Inhibitory Activity of Selected Compounds on the
PA−PB1 Interaction in the Modiﬁed ELISA
compd
modiﬁed ELISA PA−PB1
interaction assay IC50 (μM)
a
1 35.2 ± 5.1
4 >200
8 145 ± 24.0
11 40.5 ± 15.6
14 113 ± 15
15 64.5 ± 5.4
PB1(1−15)-Tat peptide 31.7 ± 10.8
aAbility of the compounds to inhibit the PA−PB1 interaction in the
ELISA performed with the DMEM serum-free medium in place of the
PBS buﬀer. Values represent the compound concentration (in μM)
that reduces the interaction between PA and PB1 by 50% (IC50).
Values represent the averages ± SD of data derived from at least two
independent experiments in duplicate.
Table 3. Activity of the Selected Compounds in the
Minireplicon Assay
compd minireplicon assay EC50 (μM)
a
1 86.6 ± 15.0
4 46.3 ± 8.7
11 30.8 ± 5.3
15 22.0 ± 4.1
RBV 23.8 ± 4.5
aThe EC50 values represent the compound concentration that reduces
by 50% the activity of FluA virus RNA polymerase in HEK 293T cells.
All values represent the averages ± SD of data derived from at least
two independent experiments in duplicate.
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poses of compounds 11, 14, and 15 can be found in Figure S1
of the Supporting Information. From the binding model, we
expected that the lack of the hydrogen bond with Lys643 would
result in a less favorable binding of the small molecules to PA,
with a decrease in the ability to disrupt the PA−PB1
interaction, but this was not conﬁrmed by the biological data.
Thus, the PA-compound complexes for the most promising
compounds (1, 11, and 15) were further investigated by means
of molecular dynamics (MD) using Schrödinger Desmond.42
After extensive equilibration, a 14 ns MD simulation was
performed for each complex starting from the most
representative docking pose. The evolution in time of the
root-mean-square deviation (RMSD) calculated on the back-
bone atoms of the protein with respect to the starting structure
is presented in panel A of Figure 4. After an initial increase due
to further equilibration of the complex, the RMSD values were
less variable in both simulations, in particular for the compound
11 in complex with PA, whose RMSD stabilized around 3.19 Å
after 3 ns of simulation. For the molecular system containing
compound 1 the average RMSD calculated between 2 and 8 ns
was 2.61 Å, while it increased up to 3.44 Å (at 12 ns) after this
time period. RMSD average values for the PA−15 complex
were 2.15 and 2.77 Å between 3 and 8 ns and after 8 ns,
respectively. The root-mean-square ﬂuctuations (RMSFs) of
the backbone atoms were then evaluated on the whole
trajectories. As shown in panel B of Figure 4, the RMSF
trends were the same for the three systems. Predictably, high
ﬂuctuations were recorded for the protein portions (residues
349−353, 372−388, 389−396, and 550−557) that were not
solved in the original crystal structure (PDB ID 2ZNL). Higher
values generally corresponded to random coils and did not
include residues interacting with the ligands (highlighted in
purple), suggesting that the structure of PB1-binding site within
PA was stable during the production MD. This was further
supported by cluster analysis that indicated high similarity of
the binding site conformation between the clusters. Figure 5
shows the superposition of the average structures of the ten
clusters obtained for compound 1, 11, and 15 complexes
(panels A, B, and C, respectively). In all panels, one structure of
the ligand (in sticks) is shown for a better identiﬁcation of the
binding site.
For a more detailed analysis of the stability of the PA−ligand
complexes, the interactions between the protein and the small
molecules were investigated on the whole 14 ns simulation
time. Occupancy percentages were also calculated and are listed
in Table 4. Hydrogen bonds and ionic interactions were the
most stable contacts between PA and the ligand, with
occupancy higher than 60%, whereas hydrophobic interactions
were generally weaker (occupancy less than 30%). An
exception was the hydrophobic interaction with Trp706 that
resulted to be stable and important, particularly for compound
11 (65.90% occupancy) and second for compound 15 (50.72%
occupancy). Predictably, the ionic contact between Lys643 side
Figure 1. Binding pose for compound 1 (orange sticks).
Figure 2. Examples of bad binding of inactive compounds. In both
images compound 1 (orange sticks) is used as a reference. (A) Binding
pose of compound 12 (cyan sticks). (B) Binding pose of compound 3
(cyan sticks).
Figure 3. Binding pose of compounds 1 (orange sticks) and
compound 11 (cyan sticks) from docking simulations.
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chain amine group and the compounds was much more
important in the complex between the protein and 1, where the
interaction involved the CN group of the small molecule.
Diﬀerently, negligible or weak ionic contacts occurred between
Lys643 and the sulfur atom of 11 and 15, respectively. Not
predicted by the docking simulation, a π−cation contact
between Lys643 side chain amine and the phenyl moiety in
position 4 in the pyridine core of the ligands was detected, and
it appeared more stable for compound 1 (74.54% versus
31.30% occupancy for 11). This interaction was, however,
negligible for compound 15 (3.54% occupancy), where the π−
cation contact was compensated by a stronger ionic interaction
of Lys643 with the sulfur atom (25.88% occupancy) and by a
weak hydrogen bond between Lys643 and the carbonyl oxygen
Figure 4. (A) Time evolution of the backbone atoms RMSD values for the complexes between PA and compounds 1 (blue line), 11 (red line), and
15 (green line). (B) RMSF evaluation of the backbone atoms for the complexes between PA and compounds 1 (blue line), 11 (red line), and 15
(green line). Ligand contacts are highlighted in purple.
Figure 5. Superposition of the average structures of the 10 clusters obtained by cluster analysis. Protein backbone is shown as ribbon and the ligand
structure in sticks. (A) Clusters for the PA−compound 1 complex. (B) Clusters for the PA−compound 11 complex. (C) Clusters for the PA−
compound 15 complex.
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of the ligand (15.78% occupancy). Importantly, Lys643 was
also involved in a water-bridge contact with the pyrimidine
nitrogen in position Z (according to Table 1; henceforth
named N1) of compound 15 with 46.09% occupancy, while this
type of interaction is not possible for compounds 1 or 11.
Remarkably, hydrogen bonds between the amide portion of
compound 11 and Val621 backbone oxygen and Gln408 side
chain amide hydrogen presented occupancy values close to
100%; while the same interactions in the other PA−compound
complexes were much weaker, with occupancy lower than 30%.
From the visualization of the trajectories a change of
conformation of 1 and of 15 were observed. In the PA−
compound 1 trajectory, while the interaction between the
ligand’s CN group and Lys643 occurred during the whole
duration of the simulation, the hydrogen bonds with Val621
and Gln408 broke after approximately 4 ns. An approximately
1.7 Å shift of the pyridine core of 1 weakened the interaction of
Trp706, placed the phenyl ring in position 4 in the pyridine in a
more suitable area for the π−cation contact with Lys643, and
enhanced the hydrophobic interactions with the areas II and III,
explaining the higher occupancy values for these contacts
(Lys643 π−cation contact and Phe707 and Phe710 hydro-
phobic interaction in particular). Furthermore, lacking the
constraints given by the hydrogen bonds involving the ligand’s
amide moiety, the methyl-substituted phenyl ring was able to
give weak T-shaped π−π stacking with Phe411 in the
hydrophobic area I. As an example of this change in
conformation, panel A of Figure 6 shows the superposition of
a frame saved from the trajectory after 4.8 ns of simulation with
the starting structure of the PA−compound 1 complex.
Similarly to what was observed for the system containing
compound 1, after approximately 3.7 ns, a 2.3 Å shift of the
central aromatic ring occurred in the PA−15 simulation. Also in
this case, the change in binding mode weakened the interaction
with Trp706, increased the hydrophobic interactions with the
areas II and III, with residues Phe411 and Phe707 in particular,
and allowed the establishment of a weak T-shaped π−π
stacking with Phe411. However, in this simulation Lys643 did
not give a π−cation interaction with the phenyl moiety, but it
interacted with compound 15 through a direct hydrogen bond
(with the carbonyl oxygen) and a water bridge (with the
pyrimidine N1 nitrogen), mainly after the compound
repositioning. Interestingly, the water molecule that bridges
the interaction between Lys643 and N1 overlaps very well the
CN nitrogen of 1, when the structures of the two complexes
extracted after 4 ns simulation are superposed (panel B of
Table 4. Ligand Interaction Occupancies for 1, 11, and 15 in
Complex with PA
occupancy (%)c
residue atoma
ligand
atom/
group
type of
contactb compd 1 compd 11 compd 15
Val621(O) NH bbHB 25.10 98.36 24.97
Gln408(HE) O scHB 22.04 97.05 14.68
Lys643(NZ) CN or S I 56.35 6.38 25.88
Lys643(HZ) O scHB 0.00 0.00 15.78
Lys643 4-phenyl Pcat 74.54 31.30 3.54
Trp706 pyridine Hyd 35.41 65.90 50.72
Phe411 3-Me-
phenyl
Hyd 16.80 15.63 27.31
Phe411 3-Me-
phenyl
PP 30.29 1.23 33.20
Cys415 3-Me-
phenyl
Hyd 5.93 6.72 3.60
Pro620 6-phenyl Hyd 4.15 0.24 0.00
Val628 6-phenyl Hyd 3.22 0.79 3.05
Leu666 4-phenyl Hyd 2.88 2.47 0.79
Phe707 4-phenyl Hyd 23.69 12.61 30.02
Phe710 4-phenyl Hyd 46.97 24.16 19.01
Phe710 4-phenyl PP 25.77 29.66 17.75
His713 4-phenyl PP 10.04 14.20 0.00
Lys643 N1d WB NAd NA 46.09
aOnly for hydrogen bonds and ionic contacts, the interacting atom is
reported in brackets using the following abbreviations: O = backbone
oxygen; HE = hydrogen of the side chain amide; NZ = nitrogen of the
side chain amine; HZ = hydrogen side chain. bType of interaction
between the protein and the ligand. Abbreviations used: bbHB =
hydrogen bond with residue backbone; scHB = hydrogen bond with
residue side chain; I = ionic interaction; Pcat = π−cation interaction;
Hyd = hydrophobic interaction; PP = π−π stacking; WB = water
bridge. cPercentage of trajectory frames in which the interaction was
recorded. dN1 = pyrimidine nitrogen in position Z in the compound,
according to Table 1 numeration; NA = not applicable.
Figure 6. (A) Change in protein−ligand interactions during the MD
simulation of 1 in complex with PA. The ligands and the protein
residues discussed in the text are shown as sticks and as lines,
respectively. Carbon atoms of the starting complex structure are
colored in orange; while the ones of the saved MD trajectory frame are
in light blue. Lighter shades of the same color were used for protein
carbon atoms. Hydrogen bonds are indicated in red. (B) Superposition
of the PA-compound 1 and PA-compound 15 complexes extracted
after 4 ns of simulation. Similar representation to panel A was used
here. Carbon atoms of compound 1 are colored in light blue; while the
ones of compound 15 are in pink. The same color was used for protein
carbon atoms. The water molecule mentioned in the text is
represented in sticks.
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Figure 6). Thus, in the case of 15, the water molecule had the
same role of the CN group of 1 in the interactions with the
protein, and this explains why the MD simulation for the PA−
15 system was more similar to the one containing 1 than to the
one containing 11.
Taken together, the results from the MD simulations suggest
that the decrease in binding aﬃnity caused by the lack of the
ionic contact between the CN group and Lys643 side chain
amine is compensated by CN-lacking compounds that display
an interesting activity in two possible ways according to the
central scaﬀold. In the case of a pyrimidine central ring (15),
N1 allows the establishment of a water bridge that mimics the
CN group. For pyridine scaﬀolds (11) that do not allow this
interaction a more stable binding conformation with stronger
interactions with other critical residues (Val621, Gln408, and
Trp706 in particular) explains the comparable activity exhibited
by the two compounds.
■ CONCLUSIONS
The increasing resistance for the current therapy against
inﬂuenza infection makes the discovery of novel drugs with a
diﬀerent mechanism of action compelling.15,43 The viral RNA
polymerase is not only essential for the viral genome replication
and transcription but also less prone to genetic variability than
the current therapeutic targets. Its activity requires the
formation of the PA−PB1 complex, making the inhibition of
this protein−protein interaction an attractive antiviral strategy.
In this work, a hit optimization process was applied to
previously identiﬁed small molecules with a 3-cyano-4,6-
diphenylpyridine scaﬀold that were identiﬁed as promising
PA−PB1 PPI.35 The molecular scaﬀold was systematically
modiﬁed, and synthetic strategies were developed. The
biological evaluation of the 15 synthesized compounds allowed
the determination of structure−activity relationships and
showed for the ﬁrst time that this novel class of molecules
with a 4,6-diphenylpyridine (or pyrimidine) nucleus is able to
inhibit the viral polymerase through the disruption of the PA−
PB1 interaction and that this can result in an antiviral eﬀect
with a good toxicity proﬁle. The biological assay results
indicated that the two phenyl rings in positions 4 and 6 are
essential for antiviral activity, while the removal of the CN
moiety at position 3 does not aﬀect compound activity.
Furthermore, the modiﬁcation of the sulfur-containing side
chain produces a decrease or complete loss in the inhibition of
the PA−PB1 interaction. Interestingly, some of these
compounds retain some antiviral activity, indicating a possible
change in the mechanism of action for them. SAR indications
were rationalized by means of docking and molecular dynamics
simulations that conﬁrmed that compounds bind to the PB1-
binding site within the C-terminal portion of PA and that the
most important interactions involve Lys643, Gln408, Val621,
Trp706, and three hydrophobic areas (I, II, and III).
Notably, three compounds (1, 11, and 15) that act on a
target that is less prone to mutations than the ones exploited in
current therapy were identiﬁed in this work. These are
promising anti-inﬂuenza molecules that will be further
developed in the future, using the binding model and the
identiﬁed SAR.
■ EXPERIMENTAL SECTION
Computational Details. Protein Preparation. The homology
model prepared for the previous study35 was used as the structure for
the inﬂuenza A PA−PB1 complex. Brieﬂy, the available structures of
the C-terminal portion of H1N1 and H5N5 inﬂuenza A virus PA
(PAC) in complex with the N-terminal PA-binding region of PB1
(PB1N, residues 1−25) were downloaded from the Protein Data Bank
(PDB ID: 2ZNL20 and 3CM8,21 respectively). Since both structure
present gaps, a more complete PAC was obtained by means of
homology modeling using the Prime tool of the Schrödinger suite.44
The model was built of the FASTA sequence of the protein (inﬂuenza
A virus, strain A/Wilson-Smith/1993 H1N1), using PDB IDs 2ZNL as
the ﬁrst template and 3CM8 as the second one. When possible, the
missing portions of 2ZNL were thus ﬁlled using 3CM8 corresponding
coordinates, while the missing residues in both structures were
modeled by the program according to the FASTA sequence. In order
to remove unfavorable contacts, the model was then energy minimized
using the all-atom OPLS force ﬁeld and Polak−Ribiere conjugate
gradient method. Water was used as a solvent, applying a continuum
solvation method. Convergence was set to 0.3 kJ mol−1, and extended
cut-oﬀs were used.
Protein Structure Comparison. The X-ray crystal structure of the
Inﬂuenza A virus H17N10 PA−PB1−PB2 trimer in complex with the
viral RNA promoter was downloaded from the Protein Data Bank
(PDB ID: 4WSB).23 The C-terminal portion of PA (PAC) was used
for comparison with that of the homology model. PyMOL45 was used
for structure superposition. The alignment of the residue sequences
saved from the superposition was assessed with Clustal Omega web
server.46
Ligand Preparation. All small molecules were built with the
Schrödinger Maestro graphical interface.47 The structures were then
processed with Schrödinger LigPrep tool48 generating for each ligand
all feasible tautomers and assigning with Epik all possible protonation
states at pH 7.0 ± 2.0, using all atom OPLS force ﬁeld.
Docking Simulations. Docking simulations were performed with
two programs: Glide40 and GOLD.41 In the docking computed with
Glide, the receptor grid was built on the PA−PB1 complex and
centered on the PB1 peptide derived from the crystal structure. The
dimensions of the box were set to 12 Å. Default settings with ﬂexible
SP mode were chosen for the docking simulation. Generated poses
were minimized after docking and a maximum of ﬁve low energy poses
were saved for each entry. The docking simulations with GOLD were
performed using GoldScore and ChemScore ﬁtness functions. The
search eﬃciency was set to 200%, and results diﬀering less than 1.5 Å
in ligand all-atom RMSD were clustered together. Also in this case ﬁve
poses were saved for each entry. All poses were visually inspected, and
consensus poses were used for SAR determination.
Molecular Dynamic Simulation (MD). The molecular dynamics
simulations were performed on the protein−ligand complexes
involving compounds 1, 11, and 15. Starting structures were retrieved
from the most representative docking poses results. The simulation
setup was performed by means of the System Builder of Schrödinger
Desmond.42 The simulation box was orthorhombic with the minimum
possible volume. A TIP4P water model and the all atom OPLS force
ﬁeld were used. The system was neutralized and a salt (NaCl)
concentration of 0.15 M was added to the system.
The simulations were performed in PBC conditions. Prior to
production, a total of 4 ns of equilibration was performed. The ﬁrst
step of equilibration was a 1 ns NVT Brownian simulation at 10 K
temperature, restraining the solute heavy atoms. All the following steps
used the Langevin algorithm. The second step of equilibration was
performed restraining solute heavy atoms in NVT conditions for 0.5 ns
at 10 K with Berendsen temperature coupling, using a 0.1 coupling
constant. In the third stage, solute heavy atoms were restrained in
NPT conditions for 0.5 ns at 10 K and 1 atm with Berendsen
temperature and pressure coupling, using 0.1 and 50.0 coupling
constants for temperature and pressure, respectively. Then, solute
heavy atoms were restrained in NPT conditions for 1 ns at 300 K and
1 atm with Berendsen temperature and pressure coupling, using 0.1
and 2.0 coupling constants for temperature and pressure, respectively.
No restraints and NPT conditions were set for the last equilibration
step that lasted 1 ns at 300 K and 1 atm with Berendsen temperature
and pressure coupling, using 0.1 and 2.0 coupling constants for
temperature and pressure, respectively. All restraints were applied with
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a force of 50.0 kcal/mol. A 14 ns NPT production MD simulation was
performed with a 2 fs time step, collecting energy and trajectory data
every 1.2 and 4.8 ps, respectively. The temperature was maintained at
300 K, and pressure was maintained at 1 atm using Langevin method
with coupling constant of 2.0 and 1.0 for pressure and temperature,
respectively. The PME method with 9.0 nm cutoﬀ radius was used for
Coulombic interactions.
The MD analysis was performed with the Desmond Simulation
Quality Analysis and the Simulation Interaction Diagram tools.42
Cluster analysis was computed with the python script trajectory_clus-
ters.py available in the Schrödinger suite. Ten clusters were identiﬁed,
confronting all trajectory frames.
Chemistry. Chloride 16 was either bought from Advanced
Chemical Intermediates Ltd. or synthesized by us through a known
procedure.49 Thiol 17a, alcohol 17b, and amine 17c were obtained
from Otava Ltd. Chlorides 23a and 23b were purchased from
Fluorochem Ltd. Chloropyrimidine 23c, pyridone 24, and thiol 29
were prepared following literature protocols.50−52 All other chemicals
were purchased from Sigma-Aldrich. THF, toluene, DME, and DCM
were distilled freshly from CaH2, all other solvents were used as
received. Unless indicated otherwise, all reactions were carried out
under an inert atmosphere. TLC analyses were performed with Merck
F254 Alumina Silica Plates using UV visualization or staining.
Microwave reactions were carried out on a Biotage Initiator. Column
puriﬁcations were carried out manually using Silicycle Ultra Pure Silica
Gel, Fluka silica gel 60 (0.04−0.063 mm), or automatically using the
Biotage equipment. All HRMS spectra were recorded on Bruker
micrOTOF MS using ESI in positive ion mode. The 1H-, 13C-, and
2D-NMR spectra were recorded on a Bruker 200, 250, 400, 500, or
600 MHz spectrometer. Systematic names for molecules were
generated using ChemBioDraw Ultra 14. Unless speciﬁed otherwise,
all ﬁnal compounds have an LC purity ≥95% at 254 nm. This was
determined using a Shimadzu HPLC/MS workstation with a LC-
20AD pump system, SPD-M20A diode array detection, and a LCMS-
2010 EV Liquid Chromatograph Mass Spectrometer. Compound
purities were calculated as the percentage peak area of the analyzed
compound by UV detection at 254 nm. The buﬀer used is a 0.4% (w/
v) NH4HCO3 solution in water, adjusted to pH 8.0 with NH4OH. The
column used is an Xbridge C18 5 μm column (50 mm × 4.6 mm).
Solvents used in this paragraph: Solvent B = 90% MeCN/10% buﬀer;
Solvent A = 90% water/10% buﬀer. The analysis was conducted using
a ﬂow rate of 1.0 mL/min, start 5% B, linear gradient to 90% B in 4.5
min, then 1.5 min at 90% B, then linear gradient to 5% in 0.5 min, then
1.5 min at 5% B, total run time of 8 min.
2-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide
(1, VUF14465). To a stirred solution of chloride 16 (0.291 g, 1.00
mmol) in DMF (20 mL) was added thiol 17a (0.326 g, 1.80 mmol)
and K2CO3 (0.207 g, 1.50 mmol). The resulting mixture was stirred
for 1 h and then quenched with water (50 mL). The precipitate was
ﬁltered and dissolved in DCM. The solution was dried over Na2SO4,
ﬁltered, and concentrated. The crude product was puriﬁed using ﬂash
chromatography (gradient starting from 5% (1% Et3N/EtOAc) in
heptane to 40% (1% Et3N/EtOAc) in heptane). This yielded the
product as a solid (110 mg, 25%). 1H NMR (500 MHz, CDCl3) δ 9.02
(s, 1H), 8.14−8.03 (m, 2H), 7.68−7.60 (m, 3H), 7.60−7.51 (m, 6H),
7.12−7.00 (m, 2H), 6.81 (s, 2H), 4.14 (s, 2H), 2.15 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 166.5, 162.6, 159.6, 155.5, 138.8, 137.7, 137.2,
135.8, 131.3, 130.6, 129.6, 129.4, 128.9, 128.5, 127.7, 125.1, 120.3,
117.4, 116.7, 115.2, 104.3, 35.2, 21.5. LCMS purity: 98+ %. HRMS [M
+ H]+ calc, 436.1478; found, 436.1467.
2-((2-Morpholino-2-oxoethyl)thio)-4,6-diphenylnicotinonitrile (2,
BAS-88). A mixture of thiol 29 (173 mg, 0.600 mmol), Cs2CO3 (195
mg, 0.599 mmol), TBAI (222 mg, 0.601 mmol), and anhydrous DMF
(8 mL) was stirred for 1 h at rt. After cooling to 0 °C, chloride 28 (147
mg, 0.899 mmol) dissolved in DMF (0.4 mL) was added. The
resulting mixture was allowed to warm to rt and stirred for 2 h. After
dilution with cold water (30 mL) and extraction with DCM (3 × 20
mL), the combined organic layers were dried over MgSO4, ﬁltered,
and concentrated. The residue was puriﬁed by column chromatog-
raphy (acetone/DCM 5/95) to obtain the product as white solid (75
mg, 30%). 1H NMR (600 MHz, CDCl3) δ 8.05−8.01 (m, 2H), 7.64−
7.60 (m, 2H), 7.59−7.50 (m, 7H), 4.31 (s, 2H), 3.74−3.66 (m, 8H).
13C NMR (150.92 MHz, CDCl3) δ 166.2, 162.2, 158.8, 154.8, 137.4,
136.0, 130.7, 130.2, 129.1, 129.0, 128.4, 127.4, 116.5, 115.4, 103.8,
66.8, 66.6, 46.6, 42.7, 32.9. LCMS purity: 95+ %. HRMS [M + H]+
calc, 416.1427; found, 416.1434.
2-((3-Cyano-4,6-diphenylpyridin-2-yl)oxy)-N-(m-tolyl)acetamide
(3, VUF14467). A microwave tube was charged with chloride 16 (0.15
g, 0.52 mmol), alcohol 17b (0.077 g, 0.47 mmol), CuI (8.9 mg, 0.047
mmol), and Cs2CO3 (0.229 g, 0.704 mmol). The tube was thoroughly
ﬂushed with N2. MeCN (5 mL) was added, and the mixture was
exposed to μW radiation (120 °C, 1.5 h). The reaction mixture was
concentrated under reduced pressure. The remaining solids were
subjected to extraction with EtOAc/water (3 × 50 mL). The organic
layer was dried over MgSO4, ﬁltered, and concentrated. The crude
product was puriﬁed by column chromatography using EtOAc/
heptane 2:8 and then (EtOAc/Et3N 99:1)/heptane 25:75. This
aﬀorded the product as a solid (14 mg, 6%). 1H NMR (500 MHz,
DMSO-d6) δ 10.35 (s, 1H), 8.23−8.15 (m, 2H), 7.87 (s, 1H), 7.80−
7.74 (m, 2H), 7.64−7.58 (m, 3H), 7.48−7.45 (m, 2H), 7.40−7.37 (m,
3H), 7.21 (t, J = 7.8 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 5.17 (s, 2H),
2.27 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 166.1, 163.3, 157.0,
156.6, 138.5, 138.0, 136.3, 135.8, 130.8, 130.2, 128.9, 128.8, 128.7,
127.5, 124.2, 120.0, 116.6, 115.2, 114.2, 92.3, 65.7, 21.2, two carbon
signals likely overlap. LCMS purity: 95+ %. HRMS [M + H]+ calc,
420.1707; found, 420.1702.
2-((3-Cyano-4,6-diphenylpyridin-2-yl)amino)-N-(m-tolyl)-
acetamide (4, VUF14466). To a stirred solution of chloride 16 (0.210
g, 0.722 mmol) in DMF (20 mL) was added amine 17c (0.214 g, 1.30
mmol) and K2CO3 (0.150 g, 1.09 mmol). The resulting mixture was
stirred for 18 h at 45 °C and then quenched with water (50 mL).
Water and DMF were evaporated, and the residue was dissolved in
DCM. This solution was dried (Na2SO4), ﬁltered, and concentrated.
The crude product was puriﬁed using ﬂash chromatography (gradient
starting from 10% (1% Et3N/EtOAc) in heptane to 80% (1% Et3N/
EtOAc) in heptane). The product was collected and again subjected to
the same puriﬁcation procedure. This yielded the product as a solid
(14 mg, 5%). 1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.06−8.04
(m, 2H), 7.68−7.60 (m, 2H), 7.58−7.50 (m, 3H), 7.48−7.46 (m, 3H),
7.29 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.19 (s, 1H), 7.14 (t, J = 7.8 Hz,
1H), 6.88 (d, J = 7.4 Hz, 1H), 6.06 (t, J = 5.5 Hz, 1H), 4.40 (d, J = 5.6
Hz, 2H), 2.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.1, 159.1,
158.8, 155.7, 139.0, 137.6, 137.5, 136.8, 130.7, 130.2, 129.2, 129.1,
129.0, 128.3, 127.5, 125.3, 120.7, 117.1, 116.9, 111.4, 89.9, 47.4, 21.5.
LCMS purity: 99+ %. HRMS [M + H]+ calc, 419.1866; found,
419.1861.
3-(3-Cyano-4,6-diphenylpyridin-2-yl)-N-(m-tolyl)propanamide
(5, VUF14519). A mixture of 6 (63 mg, 0.15 mmol) and 5% Pd/C (5
mg, 0.05 mmol) in EtOAc (20 mL) was stirred under H2 atmosphere
(1 bar) at rt. After 6 h, more Pd/C (1 mg) was added, and
hydrogenation was continued for 5 h. The black suspension was
ﬁltered over Hyﬂo. The ﬁltrate was concentrated to obtain the product
(44 mg, 67%). 1H NMR (500 MHz, CDCl3) δ 8.12 (br s, 1H), 8.03
(d, J = 7.7 Hz, 2H), 7.71 (s, 1H), 7.68−7.59 (m, 2H), 7.59−7.51 (m,
3H), 7.51−7.46 (m, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.22 (d, J = 8.0 Hz,
1H), 7.19−7.08 (m, 2H), 6.87 (d, J = 7.4 Hz, 1H), 3.67 (t, J = 6.3 Hz,
2H), 3.06 (t, J = 6.3 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 170.6, 163.9, 159.2, 154.6, 138.9, 138.2, 137.8, 136.4, 130.7,
130.2, 129.2, 128.9, 128.6, 127.8, 124.9, 120.3, 118.8, 116.7, 116.6,
106.2, 34.7, 32.0, 21.6, two carbon signals likely overlap. LCMS purity
95%. HRMS [M + H]+ calc, 418.1914; found, 418.1909.
(E)-3-(3-Cyano-4,6-diphenylpyridin-2-yl)-N-(m-tolyl)acrylamide
(6, VUF14518). A mixture consisting of chloride 16 (192 mg, 0.66
mmol), acrylamide 18 (160 mg, 0.99 mmol), NaOAc (65 mg, 0.79
mmol), nBu4NBr (234 mg, 0.73 mmol), (o-Tol)3P (40 mg, 0.13
mmol), and Pd(OAc)2 (17 mg, 0.08 mmol) in DMF (20 mL) was
stirred for 18 h at 145 °C. The green/brown suspension was diluted
with satd. aq. NaHCO3 soln. The mixture was extracted with EtOAc
(2 × 20 mL). The combined organic layers were washed with water (3
× 20 mL) and brine (1 × 20 mL). The organic layer was dried
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(MgSO4), ﬁltered, and concentrated. The residue was puriﬁed by
column chromatography (25% EtOAc in heptane) to give the product
(173 mg, 63%). 1H NMR (500 MHz, CD3OD) δ 8.36−8.29 (m, 2H),
8.17 (d, J = 14.8 Hz, 1H), 8.05 (s, 1H), 7.85 (d, J = 14.8 Hz, 1H),
7.77−7.71 (m, 2H), 7.63−7.49 (m, 8H), 7.24 (t, J = 7.8 Hz, 1H), 6.98
(d, J = 7.5 Hz, 1H), 2.36 (s, 3H). 13C NMR (126 MHz, CD3OD) δ
165.3, 160.8, 157.1, 156.1, 140.0, 139.8, 138.7, 137.8, 136.6, 131.9,
131.8, 131.2, 130.1, 130.1, 129.8, 129.8, 128.8, 126.4, 121.8, 121.5,
118.5, 117.1, 107.6, 21.6. LCMS purity 98+ %. HRMS [M + H]+ calc,
416.1763; found, 416.1762.
3-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)-
propanamide (7, VUF14520). To a stirred solution of thiol 17d (200
mg, 1.02 mmol) in MeCN (10 mL) at 0 °C were added chloride 16
(298 mg, 1.02 mmol) and K2CO3 (142 mg, 1.02 mmol). The resulting
mixture was stirred for 0.5 h at 0 °C and then 3 h at rt. The mixture
was concentrated under reduced pressure and puriﬁed by ﬂash
chromatography (gradient starting from 5% (1% Et3N/EtOAc) in
heptane to 80% (1% Et3N/EtOAc) in heptane). This aﬀorded the
product (160 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 8.11 (dd, J =
6.4, 2.7 Hz, 2H), 7.66−7.58 (m, 2H), 7.58−7.44 (m, 7H), 7.31 (s,
1H), 7.24−7.11 (m, 3H), 6.92 (d, J = 7.2 Hz, 1H), 3.79 (t, J = 7.2 Hz,
2H), 2.91 (t, J = 7.2 Hz, 2H), 2.31 (s, 3H). 13C NMR (101 MHz,
CDCl3) δ 169.1, 163.5, 158.9, 154.9, 139.1, 137.7, 137.5, 136.3, 130.9,
130.3, 129.3, 129.2, 129.0, 128.5, 127.5, 125.4, 120.7, 117.1, 116.2,
115.7, 104.3, 37.7, 26.5, 21.6. LCMS purity: 98+ %. HRMS [M + H]+
calc, 450.1635; found, 450.1638.
4-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)-
butanamide (8, VUF14523). To a stirred solution of thiol 17e (120
mg, 0.573 mmol) in MeCN (10 mL) at 0 °C were added chloride 16
(167 mg, 0.573 mmol) and K2CO3 (79 mg, 0.57 mmol). The resulting
mixture was stirred for 0.5 h at 0 °C and 3 h at rt. The resulting
mixture was concentrated under reduced pressure and puriﬁed by ﬂash
chromatography (gradient starting from 5% (1% Et3N/EtOAc) in
heptane to 80% (1% Et3N/EtOAc) in heptane). This aﬀorded the
product (20 mg, 8%). 1H NMR (400 MHz, CDCl3) δ 8.13−8.04 (m,
2H), 7.65−7.59 (m, 2H), 7.55−7.51 (m, 4H), 7.50−7.46 (m, 3H),
7.36 (s, 1H), 7.26−7.12 (m, 3H), 6.90 (d, J = 7.2 Hz, 1H), 3.55 (t, J =
6.5 Hz, 2H), 2.59 (t, J = 7.1 Hz, 2H), 2.38−2.25 (m, 5H). 13C NMR
(101 MHz, CDCl3) δ 170.2, 163.5, 158.7, 154.6, 138.9, 137.7, 137.3,
136.2, 130.6, 130.1, 129.1, 129.0, 128.8, 128.4, 127.4, 125.1, 120.4,
116.8, 115.9, 115.9, 103.9, 36.0, 30.0, 24.8, 21.5. LCMS purity: 95+ %.
HRMS [M + H]+ calc, 464.1791; found, 464.1785.
2-(Methylthio)-4,6-diphenylnicotinonitrile (9, BAS-85). To a
stirred solution of thiol 29 (144 mg, 0.499 mmol) in anhydrous
DMF (6 mL) were added Cs2CO3 (163 mg, 0.500 mmol) and TBAI
(185 mg, 0.501 mmol). The resulting mixture was stirred for 1 h at rt.
After cooling to 0 °C, MeI (0.106 g, 0.75 mmol) dissolved in DMF
(0.3 mL) was introduced via syringe. The mixture was warmed to rt
and stirred for an additional 2 h. After quenching with cold water (20
mL), the mixture was extracted with DCM (3 × 15 mL). The
combined organic layers were dried over MgSO4, ﬁltered, and the
solvents removed under vacuum. The residue was puriﬁed by column
chromatography (n-hexane/Et2O 5:1) yielding the product as a white
solid (51 mg, 34%). 1H NMR (600 MHz, CDCl3) δ 8.14−8.12 (m,
2H), 7.64−7.63 (m, 2H), 7.55−7.51 (m, 7H), 2.79 (s, 3H). 13C NMR
(150.92 MHz, CDCl3) δ 164.5, 158.4, 154.3, 137.5, 136.3, 130.6,
130.0, 129.0, 129.0, 128.4, 127.4, 115.9, 115.5, 103.7, 13.7. LCMS
purity: 97+ %. HRMS [M + H]+ calc, 303.0950; found, 303.0939.
4,6-Diphenylnicotinonitrile (10, BAS-87). PdCl2 (2.5 mg, 0.014
mmol) was added to a degassed suspension of chloride 16 (290 mg,
1.00 mmol) and NaOAc (165 mg, 2.01 mmol) in MeOH (8 mL). The
heterogeneous mixture was stirred under hydrogen (1 atm) at rt. After
36 h, the suspension was ﬁltered and the precipitate was carefully
washed with methanol (2 × 5 mL) and DCM (3 × 10 mL). The
combined organic ﬁltrates were evaporated under reduced pressure,
and DCM (20 mL) was added to the residue. The resulting solution
was ﬁltered through a thin pad of silica gel, which was washed with an
additional portion of DCM. After removal of the solvent under
reduced pressure, the crude product was puriﬁed by column
chromatography (n-hexane/Et2O 4:1), aﬀording the target compound
as white solid (97 mg, 38%). 1H NMR (600 MHz, CDCl3) δ 9.01 (s,
1H), 8.10−8.08 (m, 2H), 7.88 (s, 1H), 7.69−7.67 (m, 2H,), 7.59−7.50
(m, 6H). 13C NMR (150.92 MHz, CDCl3) δ 160.5, 154.0, 153.0,
137.5, 135.9, 130.6, 130.2, 129.2, 129.1, 128.4, 127.5, 120.4, 117.2,
106.6. LCMS purity: 99+ %. HRMS [M + H]+ calc, 257.1073; found,
257.1073.
2-((4,6-Diphenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide (11,
BAS-86). A glass tube was charged with chloride 25 (200 mg, 0.75
mmol), CuI (15 mg, 0.079 mmol), L-proline (20 mg, 0.17 mmol), and
K2CO3 (210 mg, 1.5 mmol). The tube was evacuated and ﬁlled with
argon (3 cycles). Thiol 17a (0.150 g, 0.825 mmol) dissolved in
anhydrous DME (2 mL) was introduced via syringe. The tube was
sealed and heated under reﬂux for 30 h while stirring. After cooling to
rt, the reaction mixture was partitioned between DCM (20 mL) and
satd. aq. NaCl (10 mL). The organic layer was separated, and the
aqueous layer was extracted with DCM (2 × 10 mL). The combined
organic layers were dried over MgSO4, ﬁltered, and the solvent
removed under reduced pressure. The crude product was puriﬁed by
column chromatography (DCM/MeOH 6:0.1), aﬀording the target
compound as white solid (65 mg, 21%). 1H NMR (600 MHz, CDCl3)
δ 9.97 (br s, 1H, NH), 8.08−8.04 (m, 2H), 7.71 (d, 1H, J = 1.4 Hz),
7.68−7.64 (m, 2H), 7.55−7.48 (m, 6H), 7.44 (d, 1H, J = 1.4 Hz),
7.07−6.95 (m, 2H), 6.74 (d, 1H, J = 7 Hz), 6.62 (s, 1H), 4.05 (s, 2H),
2.07 (s, 3H). 13C NMR (150.92 MHz, CDCl3) δ 168.1, 158.2, 158.0,
150.6, 138.7, 138.4, 138.2, 137.6, 129.8, 129.6, 129.3, 129.2, 128.6,
127.2, 127.2, 124.4, 119.9, 118.6, 116.4, 116.1, 35.1, 21.1. LCMS
purity: 99+ %. HRMS [M + H]+ calc, 411.1526; found, 411.1529.
2-((3-Cyano-6-phenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide
(12, VUF14469). To a stirred solution of chloride 23a (0.100 g, 0.466
mmol) in MeCN (10 mL) at 0 °C in the dark were added thiol 17a
(0.093 g, 0.51 mmol) and K2CO3 (0.097 g, 0.70 mmol). The resulting
mixture was stirred for 0.5 h at rt and then concentrated. The crude
product was puriﬁed by column chromatography (using a gradient
starting from 15% (1% Et3N/EtOAc) in heptane to 80% (1% Et3N/
EtOAc) in heptane). This provided the product as a solid (17 mg,
10%). Note: All of this work, including the column chromatography,
has to be done in the dark as the compound is photolytically unstable
(as proven by NMR and LCMS studies after exposing the compound
to day light). 1H NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.58−7.45
(m, 3H), 7.35 (s, 1H), 7.31 (d, J = 7.2 Hz, 2H), 7.28−7.20 (m, 3H),
6.98 (d, J = 7.3 Hz, 1H), 6.81 (d, J = 11.9 Hz, 1H), 3.73 (s, 2H), 2.35
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 163.7, 163.6, 155.2, 139.4,
136.9, 134.2, 131.49, 129.5, 129.4, 129.2, 126.2, 120.9, 118.8, 117.3,
114.1, 112.2, 80.2, 37.9, 21.6. LCMS purity: 95+ %. HRMS [M + H]+
calc, 360.1165; found, 360.1166.
2-((3-Cyano-4-phenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide
(13, VUF14468). To a stirred mixture of chloride 23b (100 mg, 0.466
mmol) and NaOAc (57.3 mg, 0.699 mmol) in MeCN (5 mL) was
added thiol 17a (84 mg, 0.46 mmol). The mixture was stirred
overnight at rt after which the temperature was raised to 40 °C. After 5
d, the solvent was evaporated and the remaining solids were subjected
to extraction with DCM (40 mL) and water (2 × 20 mL) then brine
(20 mL). The organic layer was dried (MgSO4), ﬁltered, and
concentrated. The crude product was puriﬁed by column chromatog-
raphy (using a gradient from 1:9 EtOAc/heptane to 5:5 EtOAc/
heptane). This yielded the product as a solid (25 mg, 15%). 1H NMR
(400 MHz, CDCl3) δ 9.03 (br, 1H), 8.67 (d, J = 5.2 Hz, 1H), 7.63−
7.50 (m, 5H), 7.36 (s, 1H), 7.27−7.24 (m, 2H), 7.19 (t, J = 7.8 Hz,
1H), 6.92 (d, J = 7.4 Hz, 1H), 4.05 (s, 2H), 2.34 (s, 3H). 13C NMR
(101 MHz, CDCl3) δ 166.5, 162.9, 154.8, 151.3, 139.2, 137.8, 135.3,
130.7, 129.4, 129.0, 128.6, 125.4, 120.8, 120.5, 116.9, 114.8, 106.5,
35.2, 21.7. LCMS purity: 98+ %. HRMS [M + H]+ calc, 360.1165;
found, 360.1167.
2-((4,6-Diphenylpyrimidin-2-yl)thio)-N-(m-tolyl)acetamide (14,
VUF14477). To a stirred solution of chloride 23c (150 mg, 0.562
mmol) in MeCN (10 mL) at 0 °C were added thiol 17a (112 mg,
0.619 mmol) and K2CO3 (117 mg, 0.844 mmol). The resulting
mixture was stirred for 5 h while being allowed to warm to rt. The
solvent was partially evaporated, and the resulting mixture was ﬁltered.
The residue was dissolved in EtOAc and subjected to column
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chromatography (100% EtOAc). This yielded the product as a solid
(120 mg, 52% yield). 1H NMR (500 MHz, CDCl3) δ 9.28 (s, 1H),
8.14−8.06 (m, 4H), 7.81 (s, 1H), 7.56−7.46 (m, 6H), 7.05 (d, J = 8.3
Hz, 1H), 6.98 (t, J = 7.8 Hz, 1H), 6.78 (s, 1H), 6.73 (d, J = 7.4 Hz,
1H), 4.00 (s, 2H), 2.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
171.1, 167.4 (split), 165.6, 138.6, 137.9 (split), 136.3, 131.6, 129.2,
128.7, 127.4, 124.8 (split), 120.1 (split), 116.5 (split), 109.2, 35.9
(split), 21.3, splitting of some peaks was observed. LCMS purity: 99+
%. HRMS [M + H]+ calc, 412.1484; found, 412.1489.
2-((4,6-Bis(4-triﬂuoromethyl)phenyl)pyrimidin-2-yl)thio)-N-(m-
tolyl)acetamide (15, VUF14525). Thiol 17a (54 mg, 0.30 mmol) and
K2CO3 (21 mg, 0.15 mmol) were added to a stirred solution of
chloride 23d (40 mg, 0.099 mmol) in MeCN (10 mL) at 0 °C. The
mixture was stirred for 2.5 h while being allowed to warm to rt. The
solvent was partially evaporated, and the resulting mixture was ﬁltered.
The residue was puriﬁed by column chromatography (heptane/EtOAc
4:1) to yield the compound as a white solid (20 mg, 37%). 1H NMR
(400 MHz, CDCl3) δ 8.79 (br s, 1H), 8.26 (d, J = 8.2 Hz, 4H), 7.89 (s,
1H), 7.81 (d, J = 8.3 Hz, 4H), 7.18 (d, J = 8.2 Hz, 1H), 7.09 (t, J = 7.8
Hz, 1H), 6.99 (s, 1H), 6.84 (d, J = 7.5 Hz, 1H), 4.05 (s, 2H), 2.18 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 171.4, 166.6, 164.5, 139.3, 138.9,
137.5, 133.3 (q, 2J = 32.8 Hz), 128.9, 127.9, 126.2 (q, 3J = 3.8 Hz),
125.2, 123.7 (q, 1J = 272.5 Hz), 120.2, 116.6, 109.6, 36.0, 21.3. LCMS
purity: 95%. HRMS [M + H]+ calc, 548.1226; found, 548.1216.
3-Mercapto-N-(m-tolyl)propanamide (17d). 3-Mercaptopropanoic
acid (1.06 g, 10.0 mmol) was combined with m-toluidine (1.093 mL,
10.0 mmol). After 1 h of stirring at rt, the mixture was heated in the
microwave for 1 h at 180 °C. The crude product was puriﬁed using
column chromatography (25% EtOAc in heptane). This aﬀorded the
product (1.64 g, 84%). 1H NMR (250 MHz, CDCl3) δ 7.39 (s, 1H),
7.32 (br s, 1H), 7.28 (d, J = 8.1 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 6.94
(d, J = 7.5 Hz, 1H), 2.93−2.85 (m, 2H), 2.67 (t, J = 6.6 Hz, 2H), 2.33
(s, 3H), 1.70 (t, J = 8.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ
169.2, 139.3, 137.7, 129.1, 125.6, 120.8, 117.2, 41.6, 21.7, 20.6. LCMS
purity: 95+ %.
4-Mercapto-N-(m-tolyl)butanamide (17e). Dihydrothiophen-
2(3H)-one (0.866 mL, 10.0 mmol) was mixed with m-toluidine
(1.09 mL, 10.0 mmol) at −5 °C. The mixture was heated in the
microwave (3 h at 120 °C, then 1 h at 160 °C, and ﬁnally 24 h at 180
°C), resulting in partial conversion. The mixture was puriﬁed using
column chromatography (25% EtOAc in heptane). This aﬀorded the
product (375 mg, 18%). 1H NMR (500 MHz, CDCl3) δ 7.38 (s, 1H),
7.29−7.26 (m, 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.16 (br s, 1H), 6.93 (d, J
= 7.4 Hz, 1H), 2.70−2.60 (m, 2H), 2.51 (t, J = 7.2 Hz, 2H), 2.34 (s,
3H), 2.04 (p, J = 7.0 Hz, 2H), 1.36 (t, J = 8.0 Hz, 1H). 13C NMR (126
MHz, CDCl3) δ 170.4, 139.2, 137.8, 129.0, 125.3, 120.6, 117.0, 35.8,
29.3, 24.2, 21.6. LCMS purity: 95+ %.
N-(m-Tolyl)acrylamide (18). Acryloyl chloride (0.41 mL, 5.3
mmol) was added to a stirred solution of m-toluidine (0.54 mL, 5.0
mmol) and Et3N (0.89 mL, 6.4 mmol) in THF (10 mL) at 0 °C. The
orange suspension was stirred for 2.5 h and poured onto brine (10
mL). The mixture was extracted with tBuOMe (2×). The organic
layers were dried over Na2SO4, ﬁltered, and concentrated. The crude
product was puriﬁed by column chromatography (25% EtOAc in
heptane) to obtain the product as a transparent oil (0.57 g, 70%). 1H
NMR (250 MHz, CDCl3) δ 7.45 (s, 1H), 7.38−7.29 (m, 1H), 7.30
(br, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.95 (d, J = 7.4 Hz, 1H), 6.43 (dd, J
= 16.8, 1.3 Hz, 1H), 6.24 (dd, J = 16.8, 10.1 Hz, 1H), 5.76 (dd, J =
10.0, 1.4 Hz, 1H), 2.34 (s, 3H). LCMS purity: 97%.
2-Chloro-4,6-diphenylpyrimidine (23c). Prepared according to a
published procedure.50 1H NMR (500 MHz, CDCl3) δ 8.19−8.12 (m,
4H), 8.02 (s, 1H), 7.59−7.48 (m, 6H).13C NMR (126 MHz, CDCl3) δ
167.7, 162.1, 135.7, 131.7, 129.1, 127.5, 111.0. LCMS purity: 95+ %.
2-Chloro-4,6-bis(4-(triﬂuoromethyl)phenyl)pyrimidine (23d).
2,4,6-Trichloropyrimidine (92 mg, 0.50 mmol), 4-(triﬂuoromethyl)-
phenylboronic acid (190 mg, 1.00 mmol), and K2CO3 (428 mg, 3.10
mmol, dissolved in a minimum amount of H2O) were mixed with 1,2-
dimethoxyethane (10 mL). The ﬂask was covered with aluminum foil.
Pd(OAc)2 (3 mg, 0.01 mmol) and PPh3 (7 mg, 0.03 mmol) were
added to the mixture. The mixture was heated at 60 °C for 24 h. The
solvent was removed by rotary evaporation, and the residue subjected
to extraction with DCM and H2O. The organic layer was washed three
times with H2O, dried over Na2SO4, ﬁltered, and concentrated. The
residue was puriﬁed by three successive column chromatography
operations (heptane/EtOAc 6:1, then PhMe/MeCOMe 8:1, and
PhMe/heptane 4:1). This yielded the product as a clear oil, which
slowly crystallized (40 mg, 20%). 1H NMR (250 MHz, CDCl3) δ 8.28
(d, J = 8.1 Hz, 4H), 8.08 (s, 1H), 7.82 (d, J = 8.3 Hz, 4H). LCMS
purity: 95%.
2-Chloro-4,6-diphenylpyridine (25). A mixture of pyridone 24
(370 mg, 1.50 mmol) and POCl3 (3.0 mL) was heated under reﬂux for
4 d. After cooling to rt the crude product was poured onto crushed ice.
The mixture was neutralized with cold 15% aq. KOH, and the
precipitate was collected by ﬁltration, washed with water, and dissolved
in DCM. The resulting solution was washed once more with diluted
KOH and water. After drying the organic layer over MgSO4 and
ﬁltration, the solvent was removed under reduced pressure. The crude
product was puriﬁed by column chromatography (DCM) yielding the
target compound as white solid (213 mg, 53%). 1H NMR (600 MHz,
CDCl3) δ 8.02−7.98 (m, 2H), 7.63 (s, 1H), 7.51−7.43 (m, 9H).
2-Chloro-1-morpholinoethan-1-one (28). To a stirred solution of
morpholine (435 mg, 4.99 mmol) in anhydrous THF (14 mL), K2CO3
(1.88 g, 10 mmol) was introduced. The reaction mixture was cooled to
0 °C, and ClCH2COCl (678 mg, 6.00 mmol) dissolved in THF (3
mL) was added dropwise. The reaction was warmed to rt and stirred
for 1 h. After ﬁltration, the ﬁltrate was evaporated aﬀording the target
compound as a viscous oil with 95% purity according to 1H NMR
spectroscopy (620 mg, 76%). 1H NMR (600 MHz, CDCl3) δ 4.08 (s,
2H), 3.78−3.72 (m, 4H), 3.66−3.62 (m, 2H), 3.56−3.52 (m, 2H).
Biological Assays. Compounds and PB1 Peptide. RBV (1-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide) and oseltamivir carboxylic
acid, the active form of oseltamivir [(3R,4R,5S)-4-acetamido-5-amino-
3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid] were purchased
from Roche. Test compounds were dissolved in dimethyl sulfoxide
(DMSO). Since photochemical degradation of compound 12 under
daylight conditions was observed during compound synthesis, all
solutions containing 12 were protected from daylight, and all
experiments with this compound were performed in the dark. The
PB1(1−15)-Tat peptide was synthesized and puriﬁed by the Peptide
Facility of CRIBI Biotechnology Center (University of Padua, Italy).
This peptide contains the ﬁrst 15 N-terminal amino acids of PB1
protein fused to the C-terminal sequence of HIV Tat protein (amino
acids 47−59).
Plasmids. Plasmids pcDNA−PB1, pcDNA−PB2, pcDNA−PA, and
pcDNA−NP, containing cDNA copies of the inﬂuenza A/PR/8/34
virus PB1, PB2, PA, and NP genes, respectively, were created as
described elsewhere53 and kindly provided by P. Digard (Roslin
Institute, University of Edinburgh, United Kingdom). Plasmid pPolI−
Flu−ﬀLuc, which contains an inﬂuenza virus-based luciferase
minireplicon vRNA under the control of the human RNA polymerase
I promoter, was provided by L. Tiley (University of Cambridge,
United Kingdom). Plasmid pRL−SV40 expressing the Renilla
luciferase was purchased from Promega.
Cells and Virus. Human embryonic kidney 293T (HEK 293T) and
MDCK cells were cultivated in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Life Biotechnologies) supplemented with 10% (v/v) fetal
bovine serum (FBS, Life Technologies) and antibiotics (100 U/mL
penicillin and 100 μg/mL streptomycin, Life Technologies). The cells
were maintained at 37 °C in a 5% CO2 humidiﬁed atmosphere.
Inﬂuenza A/PR/8/34 virus (PR8 strain, H1N1, Cambridge lineage)
was obtained from P. Digard (Roslin Institute, University of
Edinburgh, United Kingdom).
PA−PB1 Interaction Enzyme-Linked Immunosorbent Assay
(ELISA). The PA−PB1 interaction was detected as described by
Muratore et al.,29 with some modiﬁcations. Brieﬂy, microtiter plates
(Nuova Aptca) were incubated with 400 ng of 6His-PA(239−716) for 3 h
at 37 °C and then blocked with 2% BSA (Sigma) in PBS for 1 h at 37
°C. After washing, 200 ng of GST-PB1(1−25) dissolved in PBS, or GST
as a control, in the presence of test compounds at various
concentrations or DMSO, were added and incubated overnight at
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room temperature. E. coli-expressed, puriﬁed 6His-PA(239−716), GST,
and GST-PB1(1−25) proteins were obtained as previously de-
scribed.29,54 After washing, the interaction between 6His−PA(239−716)
and GST−PB1(1−25) was detected with an anti-GST monoclonal
antibody conjugated to horseradish peroxidase (HRP) (Gen-Script).
After the ﬁnal wash step, the substrate 3,3′,5,5′-tetramethylbenzidine
(TMB, KPL) was added, and the optical density was determined at
450 nm by an ELISA plate reader (Tecan Sunrise). Values obtained
from the samples treated with only DMSO were used to set as 100% of
PA−PB1 interaction. The PB1(1−15)-Tat peptide was included in all
experiments as the reference inhibitor.
In the modiﬁed PA−PB1 interaction ELISA, the assay was
performed as described above, except that GST-PB1(1−25), or GST
as a control, along with test compounds at various concentrations or
DMSO were dissolved in serum-free DMEM instead of PBS. The
PB1(1−15)-Tat peptide was included in all experiments as a positive
control for inhibition.
Plaque Reduction Assay (PRA). A conﬂuent monolayer of MDCK
cells was prepared in 12-well plates. Cells were infected with FluA
virus (PR8 strain) at 40 PFU/well in DMEM supplemented with 1
μg/mL of TPCK-treated trypsin (Worthington Biochemical Corpo-
ration) and 0.14% BSA in the presence of various concentrations of
test compounds for 1 h at 37 °C. Medium containing 1 μg/mL of
TPCK-treated trypsin, 0.14% BSA, 1.2% Avicel, and test compounds at
the same concentrations was then added. After 2 days of incubation,
cell monolayers were ﬁxed with 4% formaldehyde and stained with
0.1% toluidine blue, and viral plaques were counted. Ribavirin and
Oseltamivir were included in all experiments as reference compounds.
Cytotoxicity Assay. Cytotoxicity of test compounds was assessed in
MDCK and HEK 293T cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method, as previously re-
ported.29,55 Brieﬂy, MDCK cells (5 × 103 cells/well on 96-well
plates) and HEK 293T (2 × 104 cells/well on 96-well plates) cells
were incubated with compound at 2-fold serial dilutions from 250 μM.
After 24 or 48 h for HEK 293T and MDCK cells, respectively, MTT
solution (5 mg/mL in PBS) was added to each well, and plates were
incubated for 4 h at 37 °C. Then, a solubilization solution was added
to lyse cells. After 3 h of further incubation at 37 °C, absorbance was
read at 620 nm using an ELISA plate reader (Tecan Sunrise). Values
obtained from the wells treated with only DMSO were used to set as
100% of viable cells.
Minireplicon Assay. HEK 293T cells were seeded at a density of 2
× 105 per well into 24-well plates. After 24 h, cells were transfected
with pcDNA-PB1, pcDNA-PB2, pcDNA-PA, and pcDNA-NP
plasmids (100 ng/well of each) along with pPolI-Flu-ﬀLuc plasmid
(50 ng/well). The transfection mixture also contained pRL-SV40
plasmid (50 ng/well) to normalize variations in transfection eﬃciency.
Transfections were performed using calcium phosphate protocol in the
presence of the test compounds or DMSO. Cell medium was replaced
4 h post-transfection with DMEM containing compounds or DMSO.
At 24 h post-transfection, cells were harvested and both ﬁreﬂy
luciferase and Renilla luciferase expression were determined using the
Dual Luciferase Assay Kit from Promega. Ribavirin was included in all
experiments as the reference compound.
Interference Compounds Assessment. The structure of all
tested compounds (1−15) was examined for known classes of assay
interference compounds with the online FAF-Drug3 (Free ADME-Tox
Filtering Tool) program.56 Almost all the compounds passed the Pan
Assay Interference Compounds (PAINS)57 ﬁlter, increasing the
conﬁdence in the presented results. Only compound 6 failed to pass
the PAINS ﬁlter. However, since this molecule did not display good
activity in any of the performed in vitro assays, no further investigations
were performed.
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